Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07244406 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To evaluate the efficacy and safety of S1904 in patients with relapsed or refractory CD19+B-ALL.
Trial Details
NCT Number NCT07244406
Lead Sponsor Hebei Senlang Biotechnology Inc., Ltd.
Conditions B-ALL
Enrollment 59 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov